Press Release
ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic
NEW YORK, Oct. 27, 2020 /PRNewswire/ -- ATAI Life Sciences ("ATAI" or the "Company"), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that Neuronasal Inc. ("Neuronasal") has completed its pilot study
October 27, 2020
Press Release
ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product
NEW YORK, Aug. 24, 2020 /PRNewswire/ -- Today, ATAI Life Sciences ("ATAI" or the "Company") , a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of
August 24, 2020
Press Release
ATAI and IntelGenx enter into Feasibility Agreement to develop pharmaceutical-grade polymeric film technologies for delivery of psychedelic medicines
NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for a variety of mental health indications, announced a Feasibility Agreement with IntelGenx Corp.
August 20, 2020
Press Release
ATAI Life Sciences to Host Virtual R&D Day on July 29, 2020
BERLIN and NEW YORK, July 22, 2020 /PRNewswire/ -- ATAI Life Sciences AG , a global biotechnology company builder that envisions an end to mental illnesses, today announced that it will host a virtual Research and Development (R&D) Day for analysts and investors on Wednesday, July 29, 2020 from
July 22, 2020
Press Release
ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse
BERLIN and NEW YORK, July 9, 2020 /PRNewswire/ -- ATAI Life Sciences AG , a global biotechnology company builder that envisions an end to mental illnesses, has acquired a majority stake in New York-based pharmaceutical company Kures, which targets the important intersection between pain and opioid
July 9, 2020
Press Release
ATAI launches IntroSpect Digital Therapeutics, appoints veteran software engineer David Keene as CEO
LONDON and NEW YORK, June 22, 2020 /PRNewswire/ -- Today, ATAI Life Sciences ("ATAI" or the "Company") , a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of its digital therapeutic platform IntroSpect Digital
June 22, 2020
Displaying 97 - 102 of 107